Knopp Biosciences NIH-Funded Pain Program Advances to Second Year of HEAL Award to Discover Non-Opioid Treatments for Chronic Pain
Knopp Biosciences LLC today announced that it entered the second year of research funded by the National Institutes of Health (NIH) to utilize its Kv7 platform to discover and develop non-opioid therapies for the treatment of chronic pain. The project is funded by the NIH program called Helping to End Addiction Long-term (the NIH HEAL Initiative), which aims to improve treatments for chronic pain, curb the rates of opioid use disorder and overdose, and achieve long-term recovery from opioid addiction.
Knopp has developed a discovery platform of proprietary molecules directed to a non-opioid biological target linked to chronic pain caused by damage to nerves. The drug target is a cellular membrane potassium channel called Kv7.2/7.3, which regulates the flow of electrically charged ions required to modulate the excitability of cells. Growing scientific evidence suggests that selectively activating key Kv7 channel subtypes can control nerve-cell hyperexcitability associated with chronic pain.
“Knopp is pleased that the achievement of year one milestones positioned the company to continue research on solutions for this public health crisis,” said Michael Bozik, M.D., Chief Executive Officer of Knopp. “In year two, we expect to identify a molecule from our Kv7 platform that is suitable for further development as a potential non-opioid treatment for patients suffering from certain types of chronic pain.”
The grant funding of as much as $8 million is contingent upon the attainment of milestones over five years. Knopp’s HEAL award was one of 375 grants made across 41 states in fiscal year 2019 to apply scientific solutions to help reverse the national opioid crisis.
Knopp's Kv7 research is supported in part under Award Number U44NS093160 and Award Number U44NS115732 of the National Institute of Neurological Disorders and Stroke of the NIH. The content of this announcement is solely the responsibility of Knopp and does not necessarily represent the views of the NIH.
ABOUT KNOPP BIOSCIENCES LLC
Knopp Biosciences is a privately held drug discovery and development company focused on delivering breakthrough treatments for immunological and neurological diseases of high unmet need. Knopp’s clinical-stage oral small molecule, dexpramipexole, is in Phase 2 clinical trials in moderate-to-severe eosinophilic asthma. Knopp’s preclinical Kv7 platform is directed to small molecule treatments for developmental and epileptic encephalopathies, other rare epilepsies, neuropathic pain, and tinnitus. Please visit www.knoppbio.com.
ABOUT THE NIH HEAL INITIATIVE
The Helping to End Addiction Long-termSM Initiative, or NIH HEAL InitiativeSM, is an aggressive, trans-NIH effort to speed scientific solutions to stem the national opioid public health crisis. Launched in April 2018, the initiative is focused on improving prevention and treatment strategies for opioid misuse and addiction, and enhancing pain management. For more information, visit: https://heal.nih.gov.
This press release contains "forward-looking statements," including statements relating to planned regulatory filings and clinical development programs. All forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including the uncertainties inherent in clinical trials and product development programs, the availability of funding to support continued research and studies, the availability or potential availability of alternative therapies or treatments, the availability of patent protection for the discoveries and strategic alliances, as well as additional factors that may cause Knopp's actual results to differ from our expectations. There can be no assurance that any investigational drug product will be successfully developed or manufactured or that final results of clinical studies will be supportive of regulatory approvals required to market a product. Knopp undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.
Knopp's pipeline consists of investigational drug products that have not been approved by the U.S. Food and Drug Administration. These investigational drug products are still undergoing pre-clinical or clinical study to verify their safety and effectiveness.
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Bacardi First in Fight Against Plastic Pollution With 100% Biodegradable Spirits Bottle21.10.2020 12:00:00 EEST | Press release
Bacardi, the world’s largest family-owned spirits company, has made a giant leap forward in the fight against climate change and plastic pollution today, as it unveils plans to put the world’s most sustainable spirits bottle on shelf by 2023. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201021005281/en/ Bacardi First in Fight Against Plastic Pollution With 100% Biodegradable Spirits Bottle (Photo: Business Wire) The new 100% biodegradable bottle will replace 80 Million plastic bottles – 3,000 tons of plastic – currently produced by Bacardi across its portfolio of brands every year. This revolutionary move by Bacardi is possible thanks to its close collaboration with Danimer Scientific, a leading developer and manufacturer of biodegradable products. Petroleum-based plastics used by Bacardi today will be replaced by Danimer Scientific’s Nodax™ PHA, a biopolymer which derives from the natural oils of plant seeds such as palm,
1 GWh of Daily Solar Production Is Optimized and Monitored by Tigo Solutions Globally21.10.2020 12:00:00 EEST | Press release
This summer, Tigo Energy Inc.’s fleet of monitored module-level power electronics (MLPE) crossed a major milestone – more than 1 GWh of daily solar production. The fleet includes tens of thousands of communicating systems that span all seven continents on sites ranging from single kilowatt residential scale to multi-megawatt utility scale PV installations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201021005322/en/ Tigo's fleet of monitored PV systems spans all 7 continents and generates more than one gigawatt-hour of energy per day. (Graphic: Business Wire) “This is a significant milestone that’s the result of years of hard work by our team and our amazing network of partners that literally span the globe,” said Zvi Alon, Chairman and CEO of Tigo Energy. The daily production is tracked using Tigo’s cloud monitoring platform, which has the most granular data visibility available in the market. End customers and installat
Lionbridge International Wins 3M EMEA Supplier of the Year Award21.10.2020 11:00:00 EEST | Press release
Lionbridge International, a global leader in localisation and AI training data solutions, was honored with the 2019 3M Supplier of the Year Award in recognition of the company’s contribution to improving 3M’s competitiveness. This year, 3M recognized 12 suppliers, among thousands in its global supply base, for world class performance in providing products and/or services. These suppliers were identified and rated based on strategic spend, contract compliance, actions taken to improve 3M’s relevance and overall supplier performance (quality, delivery, responsiveness, cost, and technology roadmaps). “We are truly delighted to receive this prestigious award as it recognizes our commitment and dedication to support 3M by providing agile communications which resonate locally and amplify their global brand,” said Corinne Saunders, EMEA Managing Director, Lionbridge. “Our partnership has evolved over many years to the global engagement we have today and this award showcases the trust, shared
Ooredoo Algeria Pushes to 10Gbps its Wireless Mobile Backhaul with SIAE MICROELETTRONICA21.10.2020 10:00:00 EEST | Press release
Ooredoo a leader in mobile services, together with SIAE MICROELETTRONICA, a leading supplier of microwave and millimetre wave radio for mobile backhauling, established another record in the country pushing mobile backhaul capacity to 10Gbps. Ooredoo Algeria is unceasingly working to maximise its mobile backhaul capacity, establishing one of the most technologically advance transport infrastructure in the region. This latest achievement is part of the ongoing e-band and multiband backhaul upgrade program to a multi-gigabit infrastructure. The 10Gbps link has been achieved by upgrading an existing link operating at the maximum channel bandwidth allowed in the country of 1GHz, to a 2+0 configuration over a single antenna, effectively doubling the link capacity. “Investing in new technologies is fundamental in building resilient networks capable of withstanding unexpected situation” says Abdelkrim Melab, Head of Transmission Engineering at Ooredoo Algeria, adding “this has been possible th
Vertical Group Holding: BNP Paribas Leadership MUST Come to Malta for Questioning in Case Alleging Anti-semitism and Corruption, Court Rules, Following Extended Legal Fight Over Their Attendance21.10.2020 10:00:00 EEST | Press release
BNP Paribas’ CEO and Chairman have been ordered to appear before a Maltese court, where they face questions about the French bank’s alleged involvement with a highly controversial deal in Malta, and about serious alleged ethical, legal and professional violations at the bank, Vertical Group Holding announces today. Jean-Laurent Bonnafé and Jean Lemierre, two of France’s highest-profile executives, will be pressed to give evidence as witnesses in court concerning their roles in an alleged plot by BNP Paribas to discredit a financier of British-Israeli background who had criticized the bank over its admitted involvement in multiple criminal activities, including money-laundering for pariah regimes. Jacob Agam, alongside Malta-based Vertical Group, the international private equity group he chairs, is bringing a civil lawsuit against both men and BNP itself for what he alleges was the bank’s deliberate and unlawful destruction of the business’s assets. BNP and the executives dispute the cl
MYbank Shortens Payment Cycles for Small and Micro Businesses in the Lead up to This Year’s 11.11 Global Shopping Festival21.10.2020 07:38:00 EEST | Press release
MYbank, a leading online private commercial bank in China with a focus on serving small and micro businesses, today announced a program to provide RMB 400 billion of collateral-free credit to businesses in need as they gear up for this year’s 11.11 Global Shopping Festival. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201020006336/en/ Leveraging Ant Group's technologies, MYbank has pioneered the “310 model” that enables SMEs to apply for collateral-free business loans that take less than three minutes to apply for on a mobile phone, less than one second to approve, and requires zero human intervention. (Photo: Business Wire) As part of the dedicated program, MYbank is offering a total of RMB 200 billion in short-term loans to help small and micro business owners overcome the economic impact of the COVID-19 pandemic. This enables business owners, particularly smaller vendors with more immediate capital needs, to receive pay
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom